Effect of initial gestagen treatment on bleeding patterns in postmenopausal women receiving continuous combined hormone replacement therapy

Erkan Buyuk, Fatih Durmuşoǧlu, Caner Dökmeci

Research output: Contribution to journalArticle

Abstract

Objective: The purpose of this prospective study was to investigate the association of initial gestagen treatment with future breakthrough bleedings during continuous combined hormone replacement therapy. The predictability of progesterone challenge test on bleeding has also been investigated. Design: Eighty-six naturally postmenopausal women, of whom 38 received initial gestagen treatment (5 mg medroxyprogesterone acetate, twice daily, for 10 days) and 48 did not, were included in this prospective study. Patients were followed for 6 months, and any bleeding occurring during therapy was recorded. Results: Of the 48 patients who received continuous combined hormone replacement therapy without initial gestagen treatment, 23 (48%) had a bleeding episode. Of the 38 patients who received the same therapy with initial gestagen treatment, 13 (34.2%) had bleeding. There was a trend toward decreased breakthrough bleeding in the second group, which did not achieve significance. The mean time before bleeding was 6.76 weeks in the first group and 11.75 weeks in the second group; the difference was statistically significant (p < 0.05). Of the 28 patients with a negative progesterone challenge test at the onset of therapy, eight (28.6%) had bleeding during hormone replacement therapy. Of the 10 patients with a positive challenge, five (50%) had bleeding. The difference was not statistically significant. Conclusions: Patients who receive gestagen treatment before the onset of continuous combined hormone replacement therapy tend to experience breakthrough bleeding less frequently and later during the therapy. The response to progesterone challenge does not predict future bleeding during continuous combined hormone replacement therapy.

Original languageEnglish (US)
Pages (from-to)156-160
Number of pages5
JournalMenopause
Volume6
Issue number2
StatePublished - Jun 19 1999
Externally publishedYes

Fingerprint

Hormone Replacement Therapy
Progestins
Hemorrhage
Metrorrhagia
Progesterone
Therapeutics
Prospective Studies
Medroxyprogesterone Acetate
Bleeding Time

Keywords

  • Bleeding
  • Breakthrough bleeding
  • Progesterone challenge test

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Effect of initial gestagen treatment on bleeding patterns in postmenopausal women receiving continuous combined hormone replacement therapy. / Buyuk, Erkan; Durmuşoǧlu, Fatih; Dökmeci, Caner.

In: Menopause, Vol. 6, No. 2, 19.06.1999, p. 156-160.

Research output: Contribution to journalArticle

@article{88ee6006f28b44299573e0ac425fdb18,
title = "Effect of initial gestagen treatment on bleeding patterns in postmenopausal women receiving continuous combined hormone replacement therapy",
abstract = "Objective: The purpose of this prospective study was to investigate the association of initial gestagen treatment with future breakthrough bleedings during continuous combined hormone replacement therapy. The predictability of progesterone challenge test on bleeding has also been investigated. Design: Eighty-six naturally postmenopausal women, of whom 38 received initial gestagen treatment (5 mg medroxyprogesterone acetate, twice daily, for 10 days) and 48 did not, were included in this prospective study. Patients were followed for 6 months, and any bleeding occurring during therapy was recorded. Results: Of the 48 patients who received continuous combined hormone replacement therapy without initial gestagen treatment, 23 (48{\%}) had a bleeding episode. Of the 38 patients who received the same therapy with initial gestagen treatment, 13 (34.2{\%}) had bleeding. There was a trend toward decreased breakthrough bleeding in the second group, which did not achieve significance. The mean time before bleeding was 6.76 weeks in the first group and 11.75 weeks in the second group; the difference was statistically significant (p < 0.05). Of the 28 patients with a negative progesterone challenge test at the onset of therapy, eight (28.6{\%}) had bleeding during hormone replacement therapy. Of the 10 patients with a positive challenge, five (50{\%}) had bleeding. The difference was not statistically significant. Conclusions: Patients who receive gestagen treatment before the onset of continuous combined hormone replacement therapy tend to experience breakthrough bleeding less frequently and later during the therapy. The response to progesterone challenge does not predict future bleeding during continuous combined hormone replacement therapy.",
keywords = "Bleeding, Breakthrough bleeding, Progesterone challenge test",
author = "Erkan Buyuk and Fatih Durmuşoǧlu and Caner D{\"o}kmeci",
year = "1999",
month = "6",
day = "19",
language = "English (US)",
volume = "6",
pages = "156--160",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Effect of initial gestagen treatment on bleeding patterns in postmenopausal women receiving continuous combined hormone replacement therapy

AU - Buyuk, Erkan

AU - Durmuşoǧlu, Fatih

AU - Dökmeci, Caner

PY - 1999/6/19

Y1 - 1999/6/19

N2 - Objective: The purpose of this prospective study was to investigate the association of initial gestagen treatment with future breakthrough bleedings during continuous combined hormone replacement therapy. The predictability of progesterone challenge test on bleeding has also been investigated. Design: Eighty-six naturally postmenopausal women, of whom 38 received initial gestagen treatment (5 mg medroxyprogesterone acetate, twice daily, for 10 days) and 48 did not, were included in this prospective study. Patients were followed for 6 months, and any bleeding occurring during therapy was recorded. Results: Of the 48 patients who received continuous combined hormone replacement therapy without initial gestagen treatment, 23 (48%) had a bleeding episode. Of the 38 patients who received the same therapy with initial gestagen treatment, 13 (34.2%) had bleeding. There was a trend toward decreased breakthrough bleeding in the second group, which did not achieve significance. The mean time before bleeding was 6.76 weeks in the first group and 11.75 weeks in the second group; the difference was statistically significant (p < 0.05). Of the 28 patients with a negative progesterone challenge test at the onset of therapy, eight (28.6%) had bleeding during hormone replacement therapy. Of the 10 patients with a positive challenge, five (50%) had bleeding. The difference was not statistically significant. Conclusions: Patients who receive gestagen treatment before the onset of continuous combined hormone replacement therapy tend to experience breakthrough bleeding less frequently and later during the therapy. The response to progesterone challenge does not predict future bleeding during continuous combined hormone replacement therapy.

AB - Objective: The purpose of this prospective study was to investigate the association of initial gestagen treatment with future breakthrough bleedings during continuous combined hormone replacement therapy. The predictability of progesterone challenge test on bleeding has also been investigated. Design: Eighty-six naturally postmenopausal women, of whom 38 received initial gestagen treatment (5 mg medroxyprogesterone acetate, twice daily, for 10 days) and 48 did not, were included in this prospective study. Patients were followed for 6 months, and any bleeding occurring during therapy was recorded. Results: Of the 48 patients who received continuous combined hormone replacement therapy without initial gestagen treatment, 23 (48%) had a bleeding episode. Of the 38 patients who received the same therapy with initial gestagen treatment, 13 (34.2%) had bleeding. There was a trend toward decreased breakthrough bleeding in the second group, which did not achieve significance. The mean time before bleeding was 6.76 weeks in the first group and 11.75 weeks in the second group; the difference was statistically significant (p < 0.05). Of the 28 patients with a negative progesterone challenge test at the onset of therapy, eight (28.6%) had bleeding during hormone replacement therapy. Of the 10 patients with a positive challenge, five (50%) had bleeding. The difference was not statistically significant. Conclusions: Patients who receive gestagen treatment before the onset of continuous combined hormone replacement therapy tend to experience breakthrough bleeding less frequently and later during the therapy. The response to progesterone challenge does not predict future bleeding during continuous combined hormone replacement therapy.

KW - Bleeding

KW - Breakthrough bleeding

KW - Progesterone challenge test

UR - http://www.scopus.com/inward/record.url?scp=0032998727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032998727&partnerID=8YFLogxK

M3 - Article

C2 - 10374223

AN - SCOPUS:0032998727

VL - 6

SP - 156

EP - 160

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 2

ER -